 Karyopharm Therapeutics Inc. Nasdaq: KPTI, an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharms Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharms common stock to three newly-hired employees, with a grant date of July 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635c4. 